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Abstract
Background: Breast cancer is the most common invasive cancer among women. Currently, there are only a few
models used for therapy selection, and they are often poor predictors of therapeutic response or take months to
set up and assay. In this report, we introduce a microfluidic OrganoPlate® platform for extracellular matrix (ECM)
embedded tumor culture under perfusion as an initial study designed to investigate the feasibility of adapting this
technology for therapy selection.
Methods: The triple negative breast cancer cell lines MDA-MB-453, MDA-MB-231 and HCC1937 were selected
based on their different BRCA1 and P53 status, and were seeded in the platform. We evaluate seeding densities,
ECM composition (Matrigel®, BME2rgf, collagen I) and biomechanical (perfusion vs static) conditions. We then
exposed the cells to a series of anti-cancer drugs (paclitaxel, olaparib, cisplatin) and compared their responses to
those in 2D cultures. Finally, we generated cisplatin dose responses in 3D cultures of breast cancer cells derived
from 2 PDX models.
Results: The microfluidic platform allows the simultaneous culture of 96 perfused micro tissues, using limited
amounts of material, enabling drug screening of patient-derived material. 3D cell culture viability is improved by
constant perfusion of the medium. Furthermore, the drug response of these triple negative breast cancer cells was
attenuated by culture in 3D and differed from that observed in 2D substrates.
Conclusions: We have investigated the use of a high-throughput organ-on-a-chip platform to select therapies. Our
results have raised the possibility to use this technology in personalized medicine to support selection of appropriate
drugs and to predict response to therapy in a real time fashion.
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Background
Breast cancer is the most common invasive cancer among
women. In the United States, over 200,000 new cases are
diagnosed and about 40,000 women die from this disease
each year [1, 2]. It is also the most frequently diagnosed
cancer among women globally and the leading cause of
cancer death, with an estimated 1.7 million cases and
521,900 deaths in 2012 [3]. Based on receptor status, it
can be sub-classified into ER+, PR+, HER2+ and triple
negative breast cancer. Triple negative breast cancer has
the poorest outcome compared to other subtypes [4]. The
main FDA approved treatment for primary triple negative
breast cancer is still chemotherapy [5]. Although many
targeted therapies are being tested in this setting [6], there
is a significant need to speed up the pace of drug develop-
ment and the patient-specific application of these novel
drugs in the clinic. Therefore, in this study, we have used
triple negative breast cancer cell lines as our models. It is
well established that P53 is one of the most commonly
mutated genes in triple negative breast cancer and the
mutation status of P53 has significant biological implica-
tions [7]. BRCA1 mutation is also frequently observed in
triple negative breast cancer patients and has significant
* Correspondence: h.lanz@mimetas.com
1Mimetas BV, Leiden, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lanz et al. BMC Cancer  (2017) 17:709 
DOI 10.1186/s12885-017-3709-3
implications for the therapeutic response to PARP inhibi-
tors and platinum compounds [8–11]. Therefore, the
three triple negative cell lines used in the experiments
described subsequently were selected based on p53 and
BRCA1 mutation status (Table 1), which allowed us to test
sensitivity to relevant compounds which are reported to
have differential responses when these genetic modifica-
tions are present. We envision a possible screening strat-
egy whereby cell cycle inhibiters and other standard
chemotherapeutic agents such as, doxorubicin, and
taxanes could be tested in vitro prior to therapy selection.
Currently, only a limited number of models are
used for therapy selection, predominantly animal
based patient-derived xenograft (PDX) cancer models,
and in vitro/ex vivo models [12]. Animal models,
such as mice, are most commonly used to test the
efficacies of different therapeutic agents due to their
intrinsic complex microenvironments. However, there
are profound limitations to their ability to mimic
human-specific features. Important factors include
general differences between human and animal physi-
ology, metabolism, and tumor cell interactions with
the innate immune system, proliferation, metastasis,
and the nature of the cells themselves. For years,
patient-derived biopsies have been considered a prom-
ising tool for predictive therapy selection for breast
cancer treatment. Currently, studies are performed in
which patient biopsies are engrafted in immune-
deficient mice. The PDXs developed in this fashion
are grown in mice and subsequently exposed to
therapeutic options. However, the long and cumber-
some procedure required to develop and test PDXs
makes the outcome of these studies only relevant for
retrospective studies, rather than as a clinical decision
making tools with predictive value. On top of this,
there is considerable public and governmental pressure to
reduce animal use in experiments.
Direct in vitro culture of patient biopsies and/or tumor
resection material may offer a much faster experimental
procedure and has been used to predict drug responses
using 2D breast cancer cultures [13]. However, the
predictive value of these assays has long been ques-
tioned. Surface-attached, 2D culture techniques may
result in rapid selection of proliferating cells over quies-
cent cells. Moreover, the artificial environment presented
to cells growing on plastic surfaces, initiates uncontrolled
(de-)differentiation of cells. In recent years, 3D cell
culture, with cells embedded in extracellular matrix
(ECM), has rapidly gained popularity as an alternative
approach to standard 2D culture and studies. In general,
3D cell culture should offer a more physiologically rele-
vant microenvironment to culture, study and screen cells
isolated from biopsies. ECM components allow binding of
cell adhesion receptors that influence cell polarity, metab-
olism, fate and migration [14]. Typical 3D cell culture
phenotypes include clustering of cells, lumen formation,
reduced proliferation, as well as differentiation. In 2D
monolayer cultures, non-malignant and malignant breast
epithelial cells often exhibit similar morphologies and
doubling times. In contrast, 3D culture assays have been
shown to produce phenotypic discrimination between non-
malignant and malignant breast epithelial cells [15–17],
where non-malignant epithelial cells form polarized,
growth-arrested tubular-like structures when grown in 3D
ECM gels [18]. In contrast, malignant cancer cells form dis-
organized and proliferative spheroids [19].. In addition, it is
known that ECM-embedded culture of cells from breast
cancer biopsies yields 3D spheroids that form milk secre-
tion channels [20]. Sung and coworkers investigated human
mammary fibroblasts (HMFs) cultured in 2D and 3D and
their effects on the invasive phenotype transition of breast
cancer cells. HMFs cultured in 3D induced a more invasive
phenotype of the breast cancer cells than observed in their
2D–cultured counterparts. HMFs in 3D also produced
more signaling molecules such as fibroblast-derived HGF
that are essential for the progression of breast cancer cells
from a non-invasive to an invasive phenotype [21]. These
studies strongly suggest that engineered tissue models that
incorporate 3D culture in tumor relevant ECM and co-
culture with tumor stroma, represent promising and rele-
vant tools that allow modeling of the tumor microenviron-
ment in vitro [12, 22, 23]. Notwithstanding a great deal of
evidence for the superiority of 3D culture techniques over
2D, implementation of 3D culture on a large scale is still
cumbersome. The availability of tissue material is often lim-
iting, particularly when a range of different conditions need
to be tested. Thus, biopsy samples may need to be
expanded as 3D spheroids to ensure that enough cells are
available for a robust compound screen. Also, experimental
procedures can be cumbersome, particularly relating to the
readout and data interpretation of often highly non-
uniform cultures.
Microfluidics-based cell culture techniques have
generated tremendous interest in recent years. The
marriage between cell culture and microfabrication
techniques holds the promise of a precise spatial and
temporal control of the microenvironment and in-
corporation of mechanical stimuli such as fluid flow
as experienced by cells in vivo. This approach may
also overcome issues associated with traditional 3D
Table 1 Triple negative cell lines used in the studies based on
their p53 and BRCA1 mutation status
Cell line BRCA1 status1 P53 status2
MDA-MB-453 WT 367 30 bp deletion
MDA-MB-231 WT 280 Arg - > Lys
HCC1937 5382insC (fs > 1829X) 306 Arg - > stop
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culture methods such as non-uniformity and the lim-
ited availability of tissue materials. Such platforms,
also typically known as “organs-on-a-chip”, enable the
integration of co-culture, perfusion flow, gradients
(e.g. chemotaxis), and mechanical strains and could
ultimately lead to mimicry of crucial aspects of human
organ functionality in an in vitro setting [21, 24, 25]. For
therapy selection, crucial benefits of microfluidics-based
techniques include low volumes, the ability to engineer
the microenvironment through ECM-embedded culture,
perfusion flow and co-culture of selected tissues and cell
types. The low culture volumes are of utmost importance,
since the amount of material available from patient biop-
sies may be minimal, whereas thousands of compounds
and combinations need to be screened to tailor an optimal
and effective therapy. Recently, the value of more physio-
logically relevant microfluidic platforms for studying breast
tumor processes such as migration, invasion, extravasation,
co-culture (with stromal or/and endothelial cells) or/and
mechanical stimuli such as interstitial flow [23, 26–31] has
been demonstrated. These 3D cell culture organ-on-a-chip
systems permit high-resolution, real-time molecular im-
aging to provide insight into a drug’s mechanism of action,
as well as mechanism of toxicity. Similar to other 3D non-
microfluidic culture models, studies using these platforms
have also demonstrated differential functionalities and
responses to drug exposure in comparison to traditional 2D
plastic plate cultures and they are better at mimicking in
vivo conditions. However, their throughput is typically lim-
ited to one or a few cultures, which renders them unfit for
application to therapy selection. Recent advances have also
been made in high throughput 3D culture microfluidic plat-
forms more in line with traditional 96- and 384-well 2D
high throughput toxicity screens, as approaches in molecu-
lar and cell biology and compound discovery often require
testing of multiple conditions with controls, replicates and
dilutions in a single experimental setup [32]. A microfluidic
system for 3D cell culture was developed and used by
Montanez-Sauri et al. [27] as a proof-of-concept to screen
for the effect of ECM composition and MMP inhibition on
the phenotype, behavior, and proliferation of T47D breast
carcinoma clusters in monoculture and co-culture configu-
rations. It was also employed to screen and detect inter-in-
dividual heterogeneity of paracrine interactions
between T47D breast carcinoma cells and breast
carcinoma-associated fibroblasts of various grades or
normal mammary fibroblasts isolated from breast car-
cinoma tissue samples and adjacent normal mammary
gland tissue from patients [33]. Trietsch and
coworkers developed a stratified platform that is in-
corporated in a microtiter plate format that is fully
compatible and easy to handle with standard automa-
tion and high-content screening equipment [24]. This
platform, known as the OrganoPlate®, has been used
for iPS neuron differentiation [34] [35] and liver spheroid
culture under perfusion [24, 36].
In this paper, we employ a microfluidic organ-on-a-
chip platform based on the standard 384-well plate for-
mat and we study its potential applicability for breast
cancer therapy selection. Specifically, we optimizes
seeding densities, ECM composition and biomechanical
conditions for a series of 3 distinct breast-cancer cell lines.
Subsequently, we exposed the cells to a series of anti-
cancer agents and compared the responses to those
observed in 2D cultures. As a proof of concept for the use
of patient material we used PDX-derived human cancer
cells to determine their cisplatin sensitivity in 3D in vitro
culture. Finally, we present our view on the potential
usage of microfluidics-based 3D cell culture models for
guiding personalized therapy selection in the clinic.
Methods
Cell culture
The triple negative breast cancer cell lines MDA-MB-
453, MDA-MB-231 and HCC1937 were obtained from
the American Type Culture Collection (HTB-131,
HTB26 and CRL-2336 respectively, ATCC, Manassas,
VA). Cell lines were selected based on their different
BRCA1 and P53 status (Table 1). MDA-MB-453 and
MDA-MB-231 were maintained at 37 °C, 100% air,
and HCC1937 at 37 °C, 5% CO2. MDA-MB-453 and
MDA-MB-231 were cultured in L15 medium (ATCC)
supplemented with 10% foetal calf serum (FCS,
ATCC) and 5% penicillin/streptomycin (p/s, 100 units
penicillin/mL, 100 μg streptomycin/mL), HCC1937 in
RPMI-1640 (ATCC), 10% FCS and 5% p/s, all accord-
ing to supplier’s protocol (Additional file 1 Table S1).
For 2D culture, cells were seeded on tissue culture
grade plastic T75, 96-well flat bottom plates (Corning,
Amsterdam, The Netherlands). For 3D cell culture, cells
were trypsinized, pelleted and resuspended at the indi-
cated concentration in the appropriate extracellular matrix
(ECM). Matrigel® (Corning) was used at 9 mg/mL, and
BME2rgf (Amsbio, Abingdon, UK) at 15 mg/mL. Aliquots
of both were thawed on ice 1 day prior to seeding. Colla-
gen type I rat tail (Amsbio) was neutralized with Na2CO3
(Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands)
and buffered with 100 mM HEPES (Sigma) to a final
concentration of 4 mg/mL, prior to resuspending the cells.
PDX-tumors were generated according to previously
described protocol [37] and single tumor cell suspen-
sion generation from PDX-tumors were derived as
follows. Tumor cells from two triple negative breast
cancer PDX were isolated using the human Tumor
Dissociation Kit (Order no. 130–095-929, Miltenyi
Biotec). Briefly tumors were cut into small pieces of
2–4 mm, then transfered into the gentleMACS C
Tube and run the 7C_h_TDK3 program according to
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manufacturer’s protocol. Next the tubes were centri-
fuged to collect the sample material, and washed with
washing buffer. Mouse Cell Depletion Kit (Order no.
130–104-694, Miltenyi Biotec) was used to enrich
human cells. Specifically, cell pellet was resuspended
in buffer, 20 μL of the Mouse Cell Depletion Cocktail
added and incubated for 15 min at 4 °C. Then magnetic
separation with LS Columns was performed to collect hu-
man cells. PDX-derived cells were cultured in DMEM
(Sigma) supplemented with 10% FCS, 1% glutamax
(35.050.061 Gibco), 1% sodium pyruvate (11.360.070
Gibco), non-essential amino acids (11.140.076, Gibco) and
1% p/s (15.140.122, Gibco) at 37 °C, 5% CO2.
3D plate loading
200 μm and 400 μm 2-lane OrganoPlates® consisting of
96 microfluidic chips in parallel were obtained from
Mimetas B.V. (Leiden, the Netherlands, Fig. 1a-b and
Additional file 1 Figure S1). In each chip, 1 or 2 μL of
cells (200 μm and 400 μm plate respectively) resus-
pended in liquid ECM were patterned by the Phase-
Guide™ alongside an empty channel in the microfluidic
chip by capillary force (Fig. 1b-e). Plates were placed
under regular culture conditions to allow gelation of the
ECM (Matrigel® and BME2rgf for 15 min, collagen I for
30 min). After gelation, the remaining empty channel
was filled with media which could be passively perfused
by the levelling of two connected wells (total 100 μL
medium). By placing the plate on a modified rocker plat-
form at 7 degrees with an 8 min interval, a continuous,
bi-directional average flow of 1 μL/min was achieved.
For static conditions, plates were placed flat in the incu-
bator with equal volumes in medium wells. PDX-derived
cells were seeded at 1*107 cells/mL in a 400 μm 2-lane
plate. Medium was refreshed three times a week in the
OrganoPlate®, as for regular 2D culture.
Image analysis for cell viability and immunohistochemistry
Cell morphology was imaged with phase contrast
microscopy twice a week on a high content imaging
system the ImageXpress Micro (Molecular Devices,
Sunnyvale, CA). Viability of 3D cell cultures was
assessed with fluorescent live/dead stain (calcein-AM,
NucBlue® (Hoechst), NucRed® Dead 647, Life tech-
nologies, Bleiswijk, the Netherlands). Cultures were
incubated for 30 min with medium containing 4 μM
calcein-AM and NucBlue® and NucRed® at 2 drops/
mL. Stained cells were imaged with the ImageXpress
Micro XLS (Molecular Devices) and analysed with
Image J software (NIH, Bethesda, MD) [38].
Cells were fixed for 10 min with 3.7% formalde-
hyde (Sigma) in PBS (phasephate-buffere saline, Life
technologies #20012068). Cells washed twice for
5 min with PBS and permeabilized with 0.3% Triton
X-100 (Sigma # T8787) in PBS for 10 min. After
washing with 4% FCS in PBS, cells were incubated
with blocking solution (2% FCS, 2% bovine serum
albumin (BSA) (Sigma # A2153), 0,1% Tween 20
(Sigma # P9416) in PBS) for 45 min. Subsequently,
cells were incubated with primary antibody (rabbit –
a-phospho-H2A.X, Cell Signalling 9718S) for 60 min,
washed 3 times with PBS, incubated with secondary
antibody (goat-a-rabbit-alexa488, Life technologies,
A32731) for 30 min and washed 3 times with 4%
FCS in PBS. After nuclear stain (NucBlue®) cells
were stored in PBS at room temperature and imaged
with the ImageXpress Micro XLS.
RealTime-Glo™ and CellTiter-Glo® viability assay
Optimal seeding densities for toxicity exposures for
both 2D (96 well plate) and 3D (OrganoPlate®)
cultures were determined using the luminescent,
non-lytic, RealTime-Glo™ assay (Promega, Leiden, the
Netherlands) according to the manufacturer’s protocol.
Fig. 1 Microtiter cancer-on-a-chip plate for 3D breast cancer therapy response testing. a Photo of OrganoPlate® platform consisting of 96 perfusable
microfluidic chambers in parallel. b Closeup, (c) top and (d) side view of an individual chamber consisting of an ECM channel and a Medium channel.
Cells are premixed into a gel solution, loaded into the ECM channel by capillary action and allowed to polymerize before the introduction of medium
into the adjacent Medium channel for culture. PhaseGuide™ allows the gel solution to be pinned during the loading and polymerization step, thereby
allowing support-free and unhindered exchange with the medium. e Photo demonstrates the filling of the ECM channel using a red dye
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Upon replacement of medium in medium wells with 1X
RealTime-Glo™ reagent, measurement of the luminescent
signal was started in time on a Fluoroskan Ascent FL
microplate reader (Life technologies). For 3D cultures the
luminescent signal of the four wells aligning with the
microfluidic chip were combined for calculations.
PDX-derived cell viability in 3D cultures upon
cisplatin exposure was determined using the luminescent
CellTiter-Glo® assay (Promega). Medium was replaced by
1× solution and incubated for 45 min on the rocker at 37 °
C, 5% CO2 after which luminescent signal was measured.
Toxicity studies
For toxicity assays, olaparib (Sanbio, Uden, The
Netherlands) and paclitaxel (Sigma) were dissolved in
DMSO (Sigma). The final DMSO concentration in the
medium during exposure was 0,4%. Cisplatin (Sigma) was
dissolved prior to use in medium. Cells were seeded in 2D
and 3D 1 day before the start of exposure (t = 0). Prior to
exposure, baseline viability was determined by RealTime-
Glo™. Values were used to correct for variation in seeding
density at t = 0. MDA-MB-231 and MDA-MB-453 (BRCA
WT, P53 mutant) cell lines were exposed to increasing
concentrations of cisplatin for 48 h. HCC1937 (BRCA
mutant) was exposed to olaparib and paclitaxel for 72 h.
After exposure, viability was measured once again with
RealTime-Glo™.
Statistical analysis
All experiments are performed at least in triplicate or as
indicated. 2-way ANOVA with Tukey’s multi-comparison
post-test was performed on data using Prism 6 (GraphPad
Software, Inc., La Jolla, CA). Due to the numerous com-
parisons, P-values and significance difference between
tested conditions were presented separately in supplemen-
tary Additional file 1 Table S2 and Additional file 1 Table
S3 from their graphs in Figs. 2 and 3.
Results
Microfluidic platform for 3D breast tissue culture
Figure 1a shows the OrganoPlate® platform. This chip that
is manufactured and marketed by Mimetas, is a 384 mi-
crotiter well plate that is modified on the bottom with
microfluidic channel structures. These channel structures
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Fig. 2 Culture optimization in the microtiter microfluidic platform. Up to 96 multiple conditions such as seeding density, ECM composition, cell
types and perfusion can be investigated concurrently. Breast cancer cell line MDA-MB-453 was seeded in three different ECM compositions at
two different densities and maintained for 6 days before assessment with a live/dead assay (Calcein AM - green/NucBlue® (Hoechst) - blue/
NucRed® (propidium iodide) - Red). Scale bar = 400 μm. a Epifluorescence microscopy images showing different morphologies and viabilities of
MDA-MB-453 in Matrigel®, BME2rgf and collagen I under static and perfusion conditions at a seeding density of 10*106 cells/mL. b Graphs quantifying
the effect of ECM (Matrigel® vs BME2rgf vs collagen I), seeding density (10*106 cells/mL, black, vs 20*106 cells/mL, grey), and static vs perfusion culture on
the viability (represented as % of total cells) of MDA-MB-453 cells. Total cell number was determined by nuclear count (Hoechst staining). Total number of
dead cells was determined by positive propidium iodide staining. Viable cells was set at total cell number minus dead cell count
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are construed using a polymer microfluidic layer that is
sandwiched between two 175 μm glass plates. In this
paper, a so-called two-lane device is used for which 96
networks are present on one plate. Each microfluidic net-
work (Fig. 1b) interacts with 4 wells of the 384 well plate:
one well for ECM addition, one well for inserting growth
medium in the perfusion channel, one well as an outlet
for the perfusion channel and one well for optical interro-
gation of the microfluidic channel. The central channel
underneath the readout well is subdivided into two parts
by a PhaseGuide™. The PhaseGuide™ is a thin ridge on the
bottom of the microfluidic channel that acts as a pinning
barrier for incoming fluids [39]. Meniscus pinning is based
on the principle that a sudden change in geometry re-
quires additional energy for a liquid-air meniscus to ad-
vance beyond a barrier. The PhaseGuide™ height in this
design is 30 μm: one fourth of the microfluidic channel
height. Figure 1e shows the filling of the first lane of the
network with an ECM gel. The bottom two networks have
already been filled with ECM gel that remains pinned on
the PhaseGuide™. Once the gel is gelated, the second lane
is filled with growth medium (see Fig. 1c-d). Since gel
stratification is achieved by meniscus pinning, there is no
artificial membrane between the perfusion lane and the
ECM gel. Flow of growth medium is achieved by leveling
between reservoirs 2 and 4. By placing the platform on an
interval rocker, the platform can be placed at an angle to
assure leveling in the first direction. By changing the angle
of the platform, the direction of fluid flow is reversed.
3D triple negative breast cancer model optimization
Figure 2a shows MDA-MB-453 cells seeded in three
ECM matrices (Matrigel® vs BME2rgf vs collagen I),
under static and perfused conditions, and at two differ-
ent seeding densities (10*106 cells/mL, black, vs 20*106
cells/mL, grey). In all 6 fluorescent images, the ECM gel
lane is the top-lane. Cells were cultured for 7 days and
stained with a live cell marker (calcein-AM), a dead cell
marker (NucRed®, propidium iodide) and Hoechst (Nuc-
Blue® DNA stain, Hoechst) for total cell number.
Although cells are suspended only in the ECM gel,
they appear to be present also in the perfusion lane. This
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Fig. 3 Screening studies of breast cancer cell lines in microfluidic culture. a For paclitaxel and olaparib studies, HCC-1937 were seeded 3D in the
OrganoPlate® and 2D on tissue culture grade plastics 96-well flat bottom plates, cultured for 1 day before 72 h exposure with compounds at the
specified concentrations. Viability (as % of total cells) was quantified using an optimized RealTime-Glo™ cell viability assay. (B) MDA-MB-231 and
MDA-MB-453 were seeded for 24 h similarly and exposed to cisplatin at various concentrations for 48 h. Symbols: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001,
**** P ≤ 0.0001 using Tukey’s multiple comparison test (See supplementary documents for p-values and more detailed analysis)
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is due to meniscus stretching: The ECM gel upon pin-
ning on the PhaseGuide™ stretches along the top-side of
the chamber, thus extending into the perfusion flow lane
(see also Fig. 1d). Interestingly, cells seem to cluster
more in the overhanging part of the meniscus than in
the ECM channel, as indicated by the higher fluores-
cence intensity. Possibly the presence of oxygen and
nutrient-rich medium flow and a thinner layer of ECM
gel induces this phenotype. This hypothesis is further
supported by the static experiments, in which cells in
the ECM compartment are no longer viable, while slight
survival is still observed for the overhanging part of the
gel meniscus. Experimental results are depicted quanti-
tatively in the graphs shown in Fig. 2b. A striking differ-
ence in survival is observed between cultures under
rocker perfusion and under static conditions. Under the
first condition, survival rates are up to 80% for cells in
Matrigel® and BME-rgf for lower seeding densities, while
survival is significantly lower in collagen I. Under static
conditions cell survival falls under 60% in all cases. The
experiment clearly underlines the necessity of perfusion
flow for optimal survival. The flow not only provides
continuous refreshment of growth medium, but also
removes waste metabolites, supplies oxygen and induces
interstitial flow. A higher seeding density showed a small
decrease in viability in most conditions, likely due to re-
duced nutrient availability.
Similar flow-based improvement of viability results
were obtained for the MDA-MB-231and HCC1937 cell
lines (data not shown).
Strikingly, the three cell lines showed quite different
morphologies. Whereas MDA-MB-453 shows clustering
of cells, HCC1937 seems to display a more invasive be-
havior, occupying much more of the perfusion flow
channel. MDA-MB-231 preferentially forms a barrier tis-
sue in collagen I gel (Additional file 1 Figure S1). Opti-
mal conditions for all three cell lines in terms of survival
rate, were obtained in Matrigel® at a seeding density of
10*106 cells/mL, under perfusion flow conditions.
2D vs 3D compound exposure of breast cancer model
The optimized conditions obtained above were used for
testing dose response to chemo-therapeutic agents. An
enzymatic activity assay (Real-TimeGlo™) was used as a
measure of viability. The optimization of this assay is de-
scribed in the supplementary data and includes further
seeding density optimization showing a linear relation-
ship between cell number and enzymatic activity be-
tween 1*103 and 1*104 cells seeded per chip (Additional
file 1 Figure S2).
First, HCC1937 were exposed to paclitaxel and
olaparib (Fig. 3a). Both 2D and 3D cultures showed a
loss of viability to paclitaxel, with a more striking
effect in 3D. The maximum effect in 2D is already
achieved with the lowest concentration tested, where
for the 3D culture this is reached at 1 μM. On the
contrary, olaparib showed hardly any effect in either
2D or 3D cultures, as was observed previously [40].
The combination of olaparib and paclitaxel results in
a small, but significant increase in viability as compared to
paclitaxel in the 3D cultures.
A much more striking difference in response was
found when exposing MDA-MB-231 to cisplatin (Fig. 3b).
3D cultures responded to the drug addition at much lower
concentrations, while 2D cultures were only affected at
higher concentrations in a more dose dependent manner.
This difference was much less pronounced for MDA-MB-
453, which showed a very similar response in 2D and 3D
culture.
Finally we tested the compatibility of the 3D microflui-
dic culture platform with the 3D culture of fresh patient
material. Primary tumor cells were isolated from PDX ava-
tars of two patients and seeded in Matrigel® in the Orga-
noPlate®. The dose response curve for 48 h exposure to
cisplatin was obtained, yielding a 8,1 μM and 14.78 μM
IC50 for PDX-1 and PDX-2 respectively (Fig. 4).
Discussion
There will be wide application of the type of technology
studied here in the future. A major goal for developing
this technology is to help direct and speed up the selection
of therapies by predicting responses based on drug testing
in 3D cultures grown directly from human tumor samples.
In current therapy selection methods, most in vitro drug
screens are performed in 2D culture but the results have
often proved less than optimal. Alternatively, patient de-
rived xenograft models have become a popular in vivo
model to capture human tumor heterogeneity. However,
PDX models are expensive and labor-intensive to develop.
It also takes many months for tumors to develop in mice.
These disadvantages limit the use of PDX models in a
real-time setting to help predict treatment response and
test drugs for patients. Here, we propose the use of 3D
microfluidic models as a new approach to overcome the
issues faced with existing 2D and PDX models (Fig. 5). A
major goal for developing this technology is to create 3D
physiologically-relevant cultures of human tissue which
might allow improved and real-time selection of therapy
and prediction of response based on drug testing using 3D
culture grown directly from human tumor samples. This
approach would significantly shorten the timeline for drug
screening. Equally important, results from the 3D culture
screenings are likely to be closer to in vivo results, render-
ing them more accurate for directing the selection of ap-
propriate drugs and predicting response for individual
patients, thus, achieving personalized therapy.
In this report, we introduce a microfluidic platform
for ECM embedded tumor culture under perfusion as
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an initial study to investigate the feasibility of adapting
this technology to therapy selection. Interestingly,
drug responses in these cultures were different from
2D cultures, and also different among breast cancer
subgroups. The platform has the advantage that it
comprises 96 culture chambers that require only very
small amounts of primary tumor material, approxi-
mately 10.000 cells per data point. This makes the
platform promising for studying drug response dir-
ectly with patient biopsy material, rather than first
requiring expansion of the tumor in xenografts or
on plastic. From the results shown in this paper, we
observed that the cell lines showed improved viabil-
ity when cultured under perfusion flow conditions.
Furthermore, the different triple negative subtypes
showed different morphologies among cell types, and
within a cell type depending on the ECM compos-
ition. MDA-MB-453 showed a grape-like morph-
ology, as previously reported [41], with cluster size
depending on the ECM and the distance from the
medium perfusion channel. MDA-MB-231 displayed a
stellate phenotype in Matrigel®-type ECMs [41], with a
switch to a more boundary-like morphology when seeded
in collagen I, indicating a possible modulation of the
epithelial-to-mesenchymal switch depending on the ECM
composition used.
Differences in drug response between cancer cells
cultured in 2D and 3D have been reported previ-
ously with, in general, a higher resistance in cells
cultured in an ECM [17]. Here we observed
increased sensitivity of the MDA-MB-231 cell line
embedded in Matrigel® when exposed to cisplatin at
concentrations between 0,5 and 400 micromolar. Stable in
Day -1 PDX excision, cell 
isolation, 3D seeding
Day 0 start cisplatin 
exposure
Day 2 Cell Titre Glo














Fig. 4 Cisplatin exposure of PDX-derived human breast cancer cells in 3D
microfluidic culture. Human cancer cells from two different breast cancer
PDX avatars were isolated and seeded in 3D in the OrganoPlate® 1 day
prior to 48 h cisplatin exposure. Culture viability was quantified using the
luminescent CellTiter-Glo® cell viability assay. IC50 were determined based
on nonlinear fit of the dose response range as 8,1 μM and 14,8 μM for
PDX-1 and PDX-2 respectively
Fig. 5 Outlook: Work flow for Patient derived xenograft (PDX) vs cancer-on-a-chip drug screening. Compared to PDX drug screening, the compact
OrganoPlate® platform is expected to reduce assay time and space, and increase the throughput of screened compounds, leading to improvements in
cancer treatment planning and personalized medicine for individual patients
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vivo plasma concentrations of cisplatin are generally in
the low micromolar range [42], thus our 3D model of
MDA-MB-231 accurately predicts sensitivity at a physio-
logically relevant dose. Cisplatin IC50 values determined
for PDX-tumor isolated cells cultured in vitro in 3D are
within the same relevant dose range.
The difference between 2D and 3D response is quite
striking as cells in 3D generally show slower proliferation
rates compared to 2D culture, and are expected to be less
sensitive to anti-mitotic agents. However, Huyck et al. also
showed higher sensitivity of MDA-MB-231 cells embed-
ded in collagen to the thymidine synthesis inhibitor 5-
fluoruracil [43]. Drug response in 3D might be further
tuned by varying the composition of the ECM [17]. While
initial growth factor concentrations in various ECM gels
may impact survival of seeded cells, after a day or so of
culture, growth factor contribution to cancer cell growth
rate and viability following drug treatment is likely deter-
mined by the far higher concentration of growth factors
originating from serum in cell culture media.
Apart from a decrease in viability we could detect
an increase in the DNA damage marker phospho-
H2A.X when exposing the MDA-MB-231 to cisplatin
in 3D (Additional file 1 Figure S3) [44].
The difference in drug response between various cancer
subgroups also further validates the need to build person-
alized models for patients, revealing the importance of
using cell lines to create additional 3D models that might
be more predictive to study breast cancer-related pro-
cesses such as metastasis, invasion, and to screen com-
pounds for therapeutic intervention.
A significant amount of work lies ahead in which we will
test and evaluate primary patient biopsies in the Organo-
Plate®, assess their longevity and retrospectively compare
drug response to clinical outcome. Critical aspects to take
into account will include stroma-tumor interaction. Fur-
thermore, the model could be enhanced by including vas-
cularity and aspects of the immune system. The
OrganoPlate® platform is particularly suited for such com-
plex co-cultures, as various cell types can be arranged in or-
derly lanes, one next to the other, without the usage of
artificial membranes. The challenge, however, may lie in
the compatibility of the medium and matrix with all cell-
types needed for the co-culture. Beyond optimization of cell
culture conditions, the models need to be sufficiently
robust and validated in order to improve their usability as
an effective screening tool. While the current OrganoPlate®
platform may not totally capture the in vivo complexity of
various mechanical stimuli, cell-types, and interactions
with other organs, it is likely to offer a better predict-
ive model than conventional 2D models while being
easier and less time consuming to set up for the biol-
ogists and clinicians in comparison to models incorp-
orating advanced features or animal models.
Finally, we have described our vision for how these
organ-on-a-chip models may be implemented in the
clinic, raising the possibility of real-time screening of
compounds based on patient genetic profiles to achieve
personalized medicine.
Thus, based on our proposed workflow, application of
3D cultures isolated and grown directly from human biop-
sies or surgical samples would significantly shorten the
timeline of drug screening and results from the 3D culture
screening might be closer to in vivo results that would be
more accurate to select appropriate drugs and to predict
response for individual patients (Fig. 5). Other application
of this technology could be the use of 3D culture in drug
development to help screen compounds. We know that
3D culture has significant advantages compared with 2D
culture and that it may offer a more accurate predictive
tool for in vivo response.
Conclusions
In this study, we developed the basis for a 3D breast
cancer screening platform using a microfluidic device.
The OrganoPlate® allows the simultaneous culture of
96 perfused micro tissues, using limited amounts of
material, enabling drug screening of patient-derived
material. We showed that 3D cell culture viability is
improved by the constant perfusion of the medium.
Furthermore, it was demonstrated that the drug
response of triple negative breast cancer cells can be
attenuated by culture in 3D. Finally we showed com-
patibility of the platform with fresh dissected tumor
material in a dose range exposure.
Even though this technology is still in its infancy, our
results have already raised the possibility of using this tech-
nology in personalized medicine to help select appropriate
drugs and to predict response to therapies in a real time
fashion. Once fully developed and validated, we believe that
it will also help drug development in a more cost effective
fashion that has the potential to achieve greater accuracy.
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Additional file 1: Table S1. Culture conditions for the breast cancer
cell lines used. Table S2. Statistical analysis of culture condition studies in
Fig. 2 using Tukey’s multiple comparisons test from GraphPad version 6.
Table S3. Statistical analysis of compound screening studies in Fig. 3 using
Tukey’s multiple comparisons test generated from GraphPad version 6. Figure
S1. Raw data: Array of phase contrast, fluorescent live/dead images of the
breast cancer subgroups MDA-MB-453, MDA-MB-231 and HCC 1937 cultured
in 3D perfusion culture. Figure S2. Realtime-Glo™ (RTG) assay optimization for
HCC1937 and MDA-MB-231 in the OrganoPlate® for day 0 and day 7 culture.
Figure S3. MDA-MB-231 were cultured for 1 day in matrigel prior to 48 h
100 μM cisplatin exposure in the OrganoPlate®. (PPTX 82839 kb)
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